Acadia Pharmaceuticals | ACAD - Ebit



金融业
股票价格
USD
资产
USD 1.74B
现金及等价物
USD 956.47M
销售成本
USD 28.32M
流动资产
USD 1.22B
流动负债
USD 361.44M
债务
USD 50.79M
EBIT
USD 37.84M
EBITDA
USD -1.62M
员工
653
EPS每股收益
USD 0.18
股本和储备
USD 1.31B
销售毛利
USD 279.64M
债务利息支出
USD 0
利息收入
USD 8.06M
贷款资金
USD 0
市值
USD 4.9B
净收入
USD 31.5M
营业费用
USD 270.12M
营业利润
USD 37.84M
普通股股本
USD 171.09M
PE价格收益
11.33
税前利润
USD 46.47M
销售收入
USD 307.96M
销售和管理费用
USD 148.57M
股票
USD 108.67M
贸易债权人
USD 44.57M
应收帐款人
USD 166.33M


Ebit 更改 日
Acadia Pharmaceuticals USD 37.84M 42.45M 2026-06
ALKERMES USD -65.93M 17.65M 2026-06
Alnylam Pharmaceuticals USD 112.6M 24.99M 2026-06
Biogen USD -243.8M 758.1M 2026-06
BioMarin Pharmaceutical USD 105.6M 24.04M 2026-06
Bristol-Myers Squibb USD 299M 3.26B 2026-06
Cara Therapeutics USD -7.05M 1.11M 2026-03
Corcept Therapeutics USD 41.3M 90.9M 2026-06
Cytokinetics USD -179.17M 2.05M 2026-06
Eisai JPY 24.73B 35.04B 2026-06
Eli Lilly USD 12.46B 2.68B 2026-06
Incyte USD 700.4M 356.23M 2026-06
J&J USD 7.48B 860M 2026-06
Moderna USD -815M 573M 2026-06
Neurocrine Biosciences USD 219.9M 5.3M 2026-06
Pfizer USD -180M 5.16B 2026-06
Prothena USD 25.79M 53M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 13.29M 345.14M 2026-06
Ultragenyx Pharmaceutical USD -75M 141M 2026-06
Vanda Pharmaceuticals USD -10.28M 721K 2024-12
Vertex Pharmaceuticals USD 1.27B 129.9M 2026-06